A landmark investigation reveals Oregon’s licensed psilocybin service centers are exceeding safety and compliance standards, but economic barriers limit broader access.

Congress’s PATH Caucus outlines a federal–state roadmap to integrate psychedelic-assisted therapy into U.S. care with clinical safeguards, data tracking and provider standards.

In a unanimous move, Portland will make personal, non-commercial use and sharing of natural psychedelics a low police priority—without legalizing sales or impaired driving.

Pierce County, Nevada City and Portland advance measures to make personal use of natural psychedelics a low police priority—without legalizing them—signaling a local-first policy trend.

After pushback from operators and advisors, Oregon health officials shelved a proposal to hike psilocybin license fees. Here’s what changed, why it matters, and what to watch next.

Exploring how shared mushroom experiences foster deep human connection amidst evolving drug policy across the DMV region.

Psychedelic Alpha reports that Resilient has resubmitted its MDMA-for-PTSD application two years after a prior rejection. Here’s what to watch, timelines, and DMV impacts.

Psychedelic Alpha maps how people might gain access to psychedelics. We break it down in plain English and connect the dots to DMV cannabis delivery compliance.

After public feedback, Oregon’s health regulators shelved a proposal to double psilocybin licensing fees and will restart rulemaking, with other changes eyed for 2027.

Federal complaints say Mimi Walters and Kyrsten Sinema crossed ethical lines on psychedelic lobbying, elevating risks for drug policy debates and DMV compliance culture.

Curious about mushroom tinctures? Here’s a plain‑English guide to what they are, high‑level methods, safety, and the legal picture in DC, Maryland and Virginia—plus how other states handle it.

A close look at new research on psychedelics, authoritarian attitudes, and what an April executive action could mean—plus why DMV cannabis rules are a separate lane.

Facing budget shortfalls, Oregon will consolidate psilocybin and medical cannabis oversight and is proposing steep fee hikes. Here’s what’s changing, why it matters, and how DMV readers should read the tea leaves.

New federal signals and Big Pharma interest set the stage as Horizons comes back to New York. Here’s what DMV residents should watch, and how policy, access, and culture may evolve next.

A closed-door, two-day SAMHSA consultation in Washington, DC convened federal reps, researchers, regulators, and entrepreneurs to tackle psychedelic data gaps—no drug developers invited.

Psychedelic Alpha reports that two psychiatrists in New Zealand have been cleared to prescribe MDMA for PTSD. Here’s what happened and what DMV readers should know.

An overview of microdosing evidence for anxiety from the Microdosing Institute and its legal context across DC, Maryland, and Virginia.

Resilient resubmits MDMA-assisted therapy to FDA, Definium reports positive oral LSD Phase 3 data in GAD, and Canada funds a C$24M cannabis–brain health consortium.